BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
Signase developed novel, small molecule inhibitors of a critical cell replication pathway to inhibit tumor growth. It was spun out of the M. D. Anderson Cancer Center. The company’s assets were acquired by Systems Medicine Inc. in 2005.
Signase
Houston, TX
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.